Position in NVCT
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$139,325
New position
Shares Held
18,024
first reported quarter
Ownership
0.068%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 32%
Shared 0%
None 68%
Position in Biotechnology
Healthcare · as of Mar 31, 2026MARTINGALE ASSET MANAGEMENT L P holds $113,335,067 across 56 Biotechnology names. NVCT ranks #51 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
44,750 | $19,982,665 | |
| 2 | INCY |
Incyte Corp
|
164,646 | $15,496,481 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,861 | $13,027,483 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
46,721 | $8,832,605 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
17,762 | $3,546,183 | |
| 6 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
139,535 | $3,454,886 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,114 | $3,346,419 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
139,964 | $3,115,598 |
All Filings in NVCT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $139,325 | 18,024 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||